Intellia pauses CRISPR trials after liver injury

Has BridgeBio’s business model worked? How are executives at Moderna dealing with the company’s slump? And who will the hosts dress up as for Halloween?

We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on BridgeBio CEO Neil Kumar to discuss the company’s positive Phase 3 readouts and our colleague Jason Mast to discuss Moderna’s struggles following its Covid-19 vaccine boom.